View Older Stories View More Recent Stories

Aug 8, 2018 04:01PM G1 Therapeutics Provides Second Quarter 2018 Corporate and Financial Update
Aug 7, 2018 06:00AM G1 Therapeutics to Present at Wedbush PacGrow Healthcare Conference on August 14, 2018
Aug 7, 2018 06:00AM G1 Therapeutics to Present at Wedbush PacGrow Healthcare Conference on August 14, 2018
Aug 1, 2018 06:00AM G1 Therapeutics to Provide Second Quarter 2018 Corporate and Financial Update on August 8, 2018
Aug 1, 2018 06:00AM G1 Therapeutics to Provide Second Quarter 2018 Corporate and Financial Update on August 8, 2018
Jul 9, 2018 07:00AM G1 Therapeutics Expands Executive Leadership Team with Appointment of John Demaree as Chief Commercial Officer and Stillman Hanson as General Counsel
Jul 9, 2018 07:00AM G1 Therapeutics Expands Executive Leadership Team with Appointment of John Demaree as Chief Commercial Officer and Stillman Hanson as General Counsel
Jun 8, 2018 07:00AM G1 Therapeutics Announces Appointment of New Members to the Board of Directors
Jun 8, 2018 07:00AM G1 Therapeutics Announces Appointment of New Members to the Board of Directors
Jun 4, 2018 05:48AM G1 Therapeutics (GTHX) Announces Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 ASCO Meeting
Jun 2, 2018 09:00AM G1 Therapeutics Presents Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 2, 2018 09:00AM G1 Therapeutics Presents Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
May 16, 2018 05:07PM G1 Therapeutics to Present Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
May 16, 2018 05:07PM G1 Therapeutics to Present Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
May 3, 2018 04:01PM G1 Therapeutics Provides First Quarter 2018 Corporate and Financial Update
May 3, 2018 04:01PM G1 Therapeutics Provides First Quarter 2018 Corporate and Financial Update
May 1, 2018 07:00AM G1 Therapeutics to Present at UBS Global Healthcare Conference in May 2018
May 1, 2018 07:00AM G1 Therapeutics to Present at UBS Global Healthcare Conference in May 2018
Apr 26, 2018 07:00AM G1 Therapeutics to Provide First Quarter 2018 Corporate and Financial Update on May 3, 2018
Apr 26, 2018 07:00AM G1 Therapeutics to Provide First Quarter 2018 Corporate and Financial Update on May 3, 2018
Apr 16, 2018 06:01AM G1 Therapeutics (GTHX) Reports Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer
Apr 16, 2018 06:00AM G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer
Apr 16, 2018 06:00AM G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer
Apr 9, 2018 07:00AM G1 Therapeutics to Present Preclinical Data on CDK4/6 Inhibitors Trilaciclib and G1T38 at the 2018 American Association for Cancer Research (AACR) Annual Meeting
Apr 9, 2018 07:00AM G1 Therapeutics to Present Preclinical Data on CDK4/6 Inhibitors Trilaciclib and G1T38 at the 2018 American Association for Cancer Research (AACR) Annual Meeting
Mar 5, 2018 06:02AM G1 Therapeutics (GTHX) Reports Positive Trilaciclib Phase 2a Topline Data
Mar 5, 2018 06:00AM G1 Therapeutics Announces Positive Trilaciclib Phase 2a Topline Data Showing Robust Myelopreservation Benefits in Patients with Small Cell Lung Cancer
Mar 5, 2018 06:00AM G1 Therapeutics Announces Positive Trilaciclib Phase 2a Topline Data Showing Robust Myelopreservation Benefits in Patients with Small Cell Lung Cancer
Mar 1, 2018 07:00AM G1 Therapeutics to Present at Investor Conferences in March 2018
Mar 1, 2018 07:00AM G1 Therapeutics to Present at Investor Conferences in March 2018
Feb 21, 2018 04:01PM G1 Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights
Feb 21, 2018 04:01PM G1 Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights
Feb 14, 2018 07:00AM G1 Therapeutics to Report Fourth Quarter and Full-Year 2017 Financial Results on February 21, 2018
Feb 14, 2018 07:00AM G1 Therapeutics to Report Fourth Quarter and Full-Year 2017 Financial Results on February 21, 2018
Jan 3, 2018 07:33AM G1 Therapeutics (GTHX) Announces Research Pact on Drug Response Biomarkers for Lung Cancer
Jan 3, 2018 07:30AM GeneCentric Therapeutics Announces Research Collaboration on Drug Response Biomarkers for Lung Cancer
Jan 2, 2018 07:00AM G1 Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference
Jan 2, 2018 07:00AM G1 Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference
Dec 18, 2017 07:00AM G1 Therapeutics Added to Nasdaq Biotechnology Index
Dec 18, 2017 07:00AM G1 Therapeutics Added to Nasdaq Biotechnology Index
Nov 28, 2017 07:04AM G1 Therapeutics (GTHX) and AstraZeneca Enter Clinical Trial Collaboration in NSCLC
Nov 28, 2017 07:00AM G1 Therapeutics and AstraZeneca Enter Clinical Trial Collaboration in Non-Small Cell Lung Cancer
Aug 1, 2017 10:00AM G1 Therapeutics, Inc. (Nasdaq: GTHX) to Ring The Nasdaq Stock Market Closing Bell
View More Recent Stories View Older Stories